Phase II study of taxol in patients with advanced gastric carcinoma

Cancer Journal from Scientific American

Volumn 4, Issue 4, 1998, Pages 269-274

  Ajani, Jaffer A ^a   Fairweather, Jackie ^a   Dumas, Pamela ^a   Patt, Yehuda Z ^a   Pazdur, Richard ^a   Mansfield, Paul F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Gastric carcinoma; Paclitaxel

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYALGIA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMACH CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; STOMACH NEOPLASMS;

EID: 0031904706     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Parker SL, Tong T, Boldan, Wingo PA Cancer statistics 1997. CA Cancer J Clin 1997;47:5-27.
2. Comis S: Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rev 1974;1:221-238.
3. Kelsen DP, Magill G, Cheng E et al. Phase II trial of etoposide (VP-16) in the treatment of upper gastrointestinal malignancies. Proc Am Soc Clin Oncol 1982;1:96.
4. Lacave A, Izarzugaza I, Aparicio L et al. Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer. Am J Clin Oncol 1983;6:35-38.
5. Cullinan SA, Moertel CG, Fleming TR et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: Fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin and mitomycin. JAMA 1985;253:2061-2067.
6. Wils JA, Klein HO, Wagener DJ et al: FAMTX (5-FU, Adriamycin and methotrexate): A step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer of the Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-831.
7. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced ephagogastric cancer. J Clin Oncol 1997;15:261-267.
8. Wilke H, Wils J, Rougier P et al. Preliminary analysis of a randomized phase III trial of FAMTX vs. ELF vs. cisplatin/FU in advanced gastric cancer. Proc Am Soc Clin Oncol 1995;14:206.
9. Wani MC, Taylor HL, Wall ME et al. Plant antitumor agents VI: the isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Am Chem Soc 1971;893: 2325-2327.
10. Parness J, Horwitz SB. Taxol binds to polymerized microtubules in vitro. J Cell Biol 1981;91:479-487.
11. Schiff PB, Horwitz SB: Taxol assembles tubulin in the absence of exogenous guanosine 5′triphosphate or microtubule-associated protein. Biochemistry 1981;20:3247-3252.
12. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-1014.
13. Ajani JA, Ilson DH, Daugherty K et al. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086-1091.
14. Ajani JA, Ilson D, Bhalla K et al. Taxol, cisplatin, 5-FU: a multi-institutional phase II study in patients with carcinoma of the esophagus [abstract]. Proc Am Soc Clin Oncol 1995;14:203.
15. Ajani JA, Welch SR, Raber MN et al. Comprehensive criteria for therapy-induced toxicity. Cancer Invest 1990;8:141-153.
16. Wils J. The treatment of advanced gastric cancer. Semin Oncol 1996;23:397-406.
17. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
18. Pyrhonen S, Kuitunen T, Kouri M. A randomized, phase III trial comparing fluorouracil, epidoxorubicin, and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer [abstract]. Ann Oncol 1992;3[suppl]:12.
19. Glimelius B, Hoffmann K, Haglund U et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-190.
20. Scheithauer W, Komek G, Zeh B et al. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: a randomized trial [abstr]. Second International Conference on Biology, Prevention, and Treatment of GI Malignancy, Köln, Germany, 1995:68.
21. Eingzig AI, Lipsitz S, Wiernik PH et al. Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract: the Eastern Cooperative Oncology Group (ECOG) Results. Invest New Drugs 1995;13:223-227.
22. Tamura F, Ohtsu A, Boku N et al. Three-hour infusion of paclitaxel for advanced gastric cancer. Proc Am Soc Clin Oncol 1997; 16:307a.
23. Kim JS, Shin SW, Kim JH et al. A phase II trial of Taxol (TAX, cisplatin (CDDP), and 5-fluorouracil (FU) in patients with advanced gastric carcinoma (AGC). Proc Am Soc Clin Oncol 1997;16:293a.
24. Taguchi T. A late phase II study of docetaxel in patients with gastric cancer. Proc Am Soc Clin Oncol 1997;16:263a.
25. Sulkes A, Smyth J, Sessa C et al. Docetaxel in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994;70:380-383.
26. Einzig AI, Newberg D, Remick SC et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996;13:87-93.
27. Kambe M, Wakui A, Nakao I et al. A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancers [abstract]. Proc Am Soc Clin Oncol 1993;12:198.
28. Shirao K, Shimada Y, Kondo H et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997;15:921-927.
29. Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988,22:333-338.
30. Horikoshi N, Mitachi Y, Sakata Y et al. S-1, new oral fluoropyrimidine is very active in patients with advanced gastric cancer (early phase II study). Proc Am Soc Clin Oncol 1996;15:206.